What Does PBM Mean? Pharmacy Benefit Manager Basics

You see the letters PBM on insurance documents, news articles, and congressional hearing titles, but what does PBM mean, and why should you care? PBM stands for pharmacy benefit manager, and these companies quietly influence what you pay for prescriptions, which drugs your insurance covers, and which pharmacies you can use. Despite processing the vast majority of prescription claims in the United States, most Americans have never heard of their PBM, let alone understood how it operates.

PBM Defined: The Basics

A pharmacy benefit manager is a company that manages prescription drug benefits on behalf of health insurers, employers, unions, and government programs like Medicare and Medicaid. Think of a PBM as the middleman between the parties involved in getting a drug to you: the manufacturer that makes the medication, the pharmacy that dispenses it, and the plan sponsor (an insurer or employer) that pays for most of it.

PBMs perform several core functions. They negotiate rebates and discounts with drug manufacturers. They build and maintain formularies, which are lists of covered drugs organized by cost tiers. They process prescription claims in real time when you visit the pharmacy. They run pharmacy networks, determining which pharmacies are in-network and how much each one is reimbursed. And most large PBMs also operate their own mail-order and specialty pharmacies. For a deeper exploration, see our comprehensive PBM guide.

Why PBMs Exist

PBMs emerged in the 1960s as health insurance began covering prescription drugs more broadly. Initially, they served as claims processors, handling the paperwork between pharmacies and insurers. Over time, their role expanded into formulary design, rebate negotiation, and utilization management.

The rationale for PBMs is straightforward: by aggregating the purchasing power of millions of members, a PBM can, in theory, negotiate lower drug prices than any individual employer or insurer could on its own. The PBM industry’s trade group, the Pharmaceutical Care Management Association, argues that PBMs save the healthcare system money through negotiated discounts and utilization management. Critics dispute the size of those savings and argue that PBM profits absorb much of them. As the sections below show, this tension is now at the center of federal and state scrutiny.

The Three Dominant PBMs

The PBM market is highly concentrated. According to the Federal Trade Commission’s July 2024 interim staff report, the three largest PBMs processed nearly 80 percent of the roughly 6.6 billion prescriptions dispensed by US pharmacies in 2023, and the top six managed more than 90 percent. Understanding which one manages your benefits helps you navigate your prescription coverage.

CVS Caremark is the largest PBM by claims volume. Owned by CVS Health, it is vertically integrated with CVS Pharmacy retail locations and Aetna insurance. If your prescription card shows the Caremark logo, this is your PBM.

Express Scripts is the second largest, owned by Cigna (through its Evernorth health-services arm). It manages benefits for Cigna’s insured population and many employer plans and operates a large mail-order pharmacy.

OptumRx is the third major PBM, owned by UnitedHealth Group. It serves UnitedHealthcare members and independent employer clients, and it benefits from UnitedHealth’s data infrastructure, integrating pharmacy data with medical claims.

Each of the big three, then, sits inside a company that also owns a major insurer and pharmacies. The FTC has flagged this vertical integration as a source of potential conflicts of interest — more on that below.

How PBMs Affect What You Pay

When you wonder what does PBM mean for your wallet, the answer is significant. Your PBM shapes several factors that directly affect your out-of-pocket costs.

Formulary tier placement sets your base cost. Drugs on Tier 1 (usually generics) cost the least. Tier 2 (preferred brands) costs more. Tier 3 (non-preferred brands) and Tier 4 (specialty) cost the most. Your PBM decides which tier each drug sits on, and those decisions factor in both clinical evidence and the rebates the PBM receives from manufacturers.

Network restrictions affect where you can fill at the lowest cost. PBMs designate certain pharmacies as preferred, offering lower copays there. Using a non-preferred or out-of-network pharmacy can substantially raise your cost. For help finding the right pharmacy, the CVS Caremark pharmacy locator is a useful tool if Caremark manages your benefits.

Utilization management tools like prior authorization, step therapy, and quantity limits add another layer. These controls require you to get approval or try lower-cost alternatives before your plan covers certain medications. According to KFF, prior authorization and step therapy are common in commercial and Medicare drug plans, and they are a frequent source of patient friction and delays.

The Rebate System Explained

Rebates are at the heart of PBM economics and the center of the controversy surrounding them. Here is how they work: a drug manufacturer offers to pay the PBM a rebate — often a percentage of a drug’s list price — in exchange for favorable formulary placement. The PBM then passes some portion of that rebate back to the plan sponsor, which theoretically reduces premiums.

The problem, according to critics and to the FTC’s findings, is that this system can prioritize high-list-price drugs with large rebates over lower-priced alternatives. A drug with a high list price and a large rebate can generate more rebate revenue for the PBM than a cheaper drug with no rebate, even when the cheaper drug costs the overall system less. And because patient cost-sharing (coinsurance and deductible spending) is often based on the list price rather than the net price after rebates, patients can end up paying more at the counter than the plan’s true net cost.

The FTC examined these dynamics in detail and reported evidence that PBMs and manufacturers sometimes strike agreements that exclude lower-cost competitor drugs from a formulary in exchange for larger rebates. Federal proposals to require point-of-sale rebate pass-through — so that rebates reduce the patient’s cost directly at the pharmacy — have drawn bipartisan interest, though comprehensive federal action has not yet been enacted.

FTC Scrutiny and What It Found

PBMs have moved from obscurity to the center of federal attention. In July 2024, the FTC released an interim staff report bluntly titled “Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies.” Its central findings were that the market is dominated by a few vertically integrated firms, that those firms can steer patients toward their own affiliated pharmacies (self-preferencing), and that rebate-for-formulary arrangements can disadvantage cheaper drugs and independent pharmacies. A second interim report in January 2025 focused on markups on specialty generic drugs dispensed through PBM-affiliated pharmacies.

Separately, in September 2024 the FTC brought an administrative action targeting the three largest PBMs over their rebate practices for insulin, alleging those practices contributed to inflated list prices. The PBM industry has contested the FTC’s characterizations, arguing that its reports are incomplete and that PBMs lower net drug spending. The dispute is ongoing, and readers should treat specific claims from either side as contested rather than settled — verify the current status of FTC actions and any resulting reforms.

PBMs and Medicare Part D

Medicare Part D prescription drug coverage flows through PBMs. Every Part D plan contracts with a PBM to manage its formulary, process claims, and negotiate prices. According to CMS, the major PBMs administer the large majority of Part D enrollment.

The Inflation Reduction Act of 2022 introduced significant changes affecting how PBMs operate within Medicare. Medicare has begun negotiating prices directly with manufacturers for certain high-cost drugs, which can reduce the PBM’s role in price-setting for those medications. And Part D now includes a hard annual out-of-pocket cap for beneficiaries — it began at $2,000 in 2025 and is indexed upward in later years — which reshapes the financial landscape for patients and PBMs alike.

For more on how Medicare members can optimize their pharmacy benefits, see our guide to the best mail order pharmacy for Medicare.

The Regulatory Outlook

PBM regulation is accelerating. At the state level, more than 40 states have enacted PBM-related laws, according to the National Conference of State Legislatures. These range from licensing and registration requirements to transparency mandates and bans on spread pricing (charging a plan more than the PBM reimburses the pharmacy, and keeping the difference) in state programs.

Federal proposals target several PBM practices, including rebate retention, formulary manipulation, pharmacy network restrictions, spread pricing, and vertical-integration conflicts of interest. While comprehensive federal PBM reform has not yet passed, the sustained bipartisan attention and active FTC scrutiny suggest that changes are likely in the coming years. Our healthcare policy guide tracks these developments and provides context for how PBM regulation fits into the broader healthcare policy landscape.

Frequently Asked Questions

What does PBM stand for?

PBM stands for pharmacy benefit manager. These companies manage prescription drug benefits for health plans, negotiating prices, building formularies, and processing claims. See our PBM meaning article for additional context.

How do I find out which PBM manages my prescriptions?

Check your prescription benefit card. The PBM’s name or logo is usually printed on the front. You can also call the number on the back of your card and ask. The most common PBMs are CVS Caremark, Express Scripts, and OptumRx.

Can I switch PBMs?

Not directly. Your employer or insurer selects the PBM as part of the plan design. However, you may be able to choose between plan options during open enrollment, and different plans may use different PBMs.

Are PBMs regulated?

Increasingly, yes, at both state and federal levels. More than 40 states have PBM laws, and federal agencies including the FTC and CMS oversee various aspects of PBM operations. The FTC issued critical reports in 2024 and 2025 and has taken enforcement action, though comprehensive federal reform legislation has not yet been enacted.

Do PBMs increase or decrease drug prices?

This is intensely debated. PBMs say they reduce net costs through negotiation. Critics and the FTC argue that some PBM practices — particularly the rebate system and self-preferencing — can inflate list prices and increase what patients pay. The reality likely varies by drug, plan, and specific PBM practice.

Why Understanding PBMs Matters

Now that you know what PBM means, you can engage with your prescription benefits more effectively. Check your formulary before accepting a new prescription. Use preferred pharmacies to minimize copays. Ask about generic alternatives when a brand-name drug sits on a high tier. Compare the cash price (including discount-card prices) against your insurance copay, since it is occasionally lower. And if you face a coverage denial, exercise your right to appeal. PBMs are powerful intermediaries, but informed members have tools to work within the system to their advantage. For a deeper dive into PBM operations and their role in healthcare, read our guide on PBMs in healthcare.

Sources

• Federal Trade Commission — Interim Staff Report on Prescription Drug Middlemen (July 2024): top 3 PBMs ~80% of ~6.6B prescriptions in 2023; top 6 >90%; vertical integration, self-preferencing, and rebate concerns
• Federal Trade Commission — FTC.gov (second interim PBM report, January 2025; September 2024 administrative action on insulin rebate practices)
• KFF — Prior authorization, formularies, and utilization management
• Centers for Medicare & Medicaid Services (CMS) — Medicare Part D and Inflation Reduction Act drug provisions
• National Conference of State Legislatures — State PBM legislation